These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 77201)

  • 1. Cytostasis against self-antigens.
    De Giorgi L; Matossian-Rogers A; Festenstein H
    Clin Exp Immunol; 1978 Feb; 31(2):209-17. PubMed ID: 77201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytostatic effector cells generated in vivo against M locus determinants.
    Matossian-Rogers A; Festenstein H
    Clin Exp Immunol; 1977 Feb; 27(2):335-9. PubMed ID: 66115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of H-2 restriction in cell-mediated cytotoxicity and transplantation immunity to Leukemia-associated antigens.
    Ting CC; Law LW
    J Immunol; 1977 Apr; 118(4):1259-64. PubMed ID: 191534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
    Matsumoto T; Himeno K; Mitani M; Mori K; Miake S; Nomoto K
    J Clin Lab Immunol; 1986 Feb; 19(2):83-9. PubMed ID: 3083105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for cytostatic T cell activity in the effector mechanism against syngeneic TMT mammary tumor cells in mice.
    Kurata S; Tsuchiya T; Norimura T; Yamashita U
    J Immunol; 1983 Jan; 130(1):496-500. PubMed ID: 6600195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modification of the anti-tumour immune response by suppressor gene products of lymphoid cells.
    De Giorgi L; Matossian-Rogers A; Festenstein H
    Immunology; 1979 Apr; 36(4):711-8. PubMed ID: 108205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of the lymphoproliferative disease inducer gene Arp with autoimmunity and resistance to tumour growth.
    Matossian-Rogers A
    Clin Exp Immunol; 1985 Sep; 61(3):614-23. PubMed ID: 2416497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of antibody in the inhibition of the growth of Meth.A tumour in syngeneic experiments in vivo and in vitro.
    Farram E; Festenstein H; de Giorgi L
    Clin Exp Immunol; 1978 Sep; 33(3):377-85. PubMed ID: 737892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy of disseminated malignancies. Role of alien histocompatibility antigens on cancer cells and effectiveness of cells from alloimmunized donors.
    Tempelis LD; Wasik MR; Bortin MM
    Ric Clin Lab; 1983; 13(2):163-82. PubMed ID: 6604934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro studies on the cellular immune response of tumor-bearing mice to SV40-transformed cells.
    Blasecki JW; Tevethia SS
    J Immunol; 1975 Jan; 114(1 Pt 1):244-9. PubMed ID: 163278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH; Daynes RA; Hodes RJ
    J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of class 1 and class 2 major histocompatibility complex antigens: help to allogeneic K and D antigens does not involve I recognition.
    Swain SL
    J Immunol; 1981 Jun; 126(6):2307-9. PubMed ID: 6164727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Destruction of experimental malignant melanoma by mediators of cellular immunity.
    Youdim S
    Cancer Res; 1977 Feb; 37(2):572-7. PubMed ID: 401681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
    Tomita Y; Mayumi H; Eto M; Nomoto K
    J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal cell populations during tumour injection.
    De Heer E; De Groot JW; Den Otter W; Dullens HF
    Int J Tissue React; 1982; 4(1):81-90. PubMed ID: 7085002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
    Yoshida R; Yoneda Y; Kuriyama M; Kubota T
    J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Specificity of cell mediated cytotoxicity. I. Cytotoxic reactions in H-2 system after allogeneic sensitization in vivo].
    Schulze HA; Brock J; Siegl E
    Allerg Immunol (Leipz); 1982; 28(2):109-17. PubMed ID: 6182781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two types of allograft-induced cytotoxic macrophage, one against allografts and the other against syngeneic or allogeneic tumor cells.
    Yoneda Y; Tashiro-Yamaji J; Kubota T; Yoshida R
    Microbiol Immunol; 2008 Jul; 52(7):349-56. PubMed ID: 18667033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T lymphocyte responses to multiple minor histocompatibility antigens generate both self-major histocompatibility complex-restricted and cross-reactive cytotoxic T lymphocytes.
    Tremblay N; Fontaine P; Perreault C
    Transplantation; 1994 Jul; 58(1):59-67. PubMed ID: 8036709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.